Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT)

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
John E LevineDaniel J Weisdorf

Abstract

We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 microg/kg to 720 microg/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients. Treatment with palifermin showed beneficial effects on mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconstitution, have been seen in experimental transplant models. Therefore, we investigated whether with longer follow-up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients.

References

Jan 14, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mats RembergerOlle Ringdén
Nov 8, 2003·International Journal of Hematology·James L M FerraraTakanori Teshima
Jun 1, 2004·International Journal of Hematology·Gérard Socié
Dec 17, 2004·The New England Journal of Medicine·Ricardo SpielbergerChristos Emmanouilides
Nov 24, 2005·Blood·Onder AlpdoganMarcel R M van den Brink

❮ Previous
Next ❯

Citations

Feb 14, 2012·Bone Marrow Transplantation·M H JagasiaE K Waller
Jan 4, 2013·Stem Cells Translational Medicine·Anthony D Sung, Nelson J Chao
Sep 22, 2010·Annals of Internal Medicine·John F Deeken, Louis M Weiner
Sep 19, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Judith E Raber-DurlacherUNKNOWN Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (
Aug 27, 2009·Biologics : Targets & Therapy·Andrei BaraschKen Tilashalski
May 26, 2012·Nature Reviews. Immunology·Hao Wei Li, Megan Sykes
Jun 2, 2011·Immunological Investigations·Thomas LehrnbecherThomas Klingebiel
Jul 16, 2011·Leukemia & Lymphoma·Amittha Wickrema
Jul 10, 2012·Expert Opinion on Pharmacotherapy·Andrew R Rezvani, Rainer F Storb
Mar 23, 2011·Expert Opinion on Drug Metabolism & Toxicology·Christian WeigeltGuido Kobbe
Nov 21, 2013·Journal of Cellular and Molecular Medicine·Saroj Vadhan-RajMarcel R M van den Brink
Aug 21, 2012·Annals of the New York Academy of Sciences·Lena OevermannRupert Handgretinger
Mar 21, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Diana T NguyenRicardo Spielberger
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Evert-Jan WilsJan J Cornelissen
Jun 11, 2014·Blood·Shernan G HoltanDaniel J Weisdorf
May 3, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrea S Henden, Geoffrey R Hill

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.